<p>Coeptis Therapeutics Holdings, Inc.（納斯達克代碼：COEP - 獲取免費報告）週二股價上漲了 12.2%。該股最高交易價為 17.13 美元，最後交易價為 17.00 美元。在午盤交易中，約有 77,154 股易手，較日均交易量 40,114 股增加了 92%。該股此前收盤價為 15.15 美元。</p>
<p>獲取 <strong>Coeptis Therapeutics</strong> 的提醒：</p>
<h2>分析師升級與降級</h2>
<p>另外，Weiss Ratings 在 10 月 8 日星期三的研究報告中重申了對 Coeptis Therapeutics 股票的 “賣出（e+）” 評級。一位投資分析師對該股給予了賣出評級，根據 MarketBeat.com 的數據，Coeptis Therapeutics 目前的共識評級為 “賣出”。</p>
<p><strong>閲讀我們關於 Coeptis Therapeutics 的最新股票報告</strong></p>
<h2>Coeptis Therapeutics 股價上漲 12.2%</h2>
<p>該股市值為 9078 萬美元，市盈率為-5.18，貝塔值為-0.50。該公司的 50 日簡單移動平均線為 15.16 美元，200 日簡單移動平均線為 11.96 美元。公司的速動比率為 0.83，流動比率為 2.21，債務股本比率為 0.01。</p>
<h2>機構投資者對 Coeptis Therapeutics 的看法</h2>
<p>一家對沖基金最近在 Coeptis Therapeutics 股票中購買了新股份。Yorkville Advisors Global LP 在第三季度購買了 Coeptis Therapeutics Holdings, Inc.（納斯達克代碼：COEP - 免費報告）的新股份，根據其最近向證券交易委員會提交的 13F 文件，該基金購買了 8,000 股該公司的股票，價值約為 140,000 美元。Coeptis Therapeutics 佔 Yorkville Advisors Global LP 投資組合的約 0.0%，使該股成為其第 24 大持股。截至其最近的 SEC 文件，Yorkville Advisors Global LP 持有 Coeptis Therapeutics 的 0.17%。機構投資者持有該公司 13.88% 的股票。</p>
<h2>關於 Coeptis Therapeutics</h2>
<p>（獲取免費報告）</p>
<p>Coeptis Therapeutics Holdings, Inc.是一家生物製藥公司，開發針對癌症患者的細胞治療平台。其產品組合包括 CD38-GEAR-NK，一種用於治療與 CD38 相關的癌症的細胞治療，包括多發性骨髓瘤、慢性淋巴細胞白血病和急性髓性白血病；SNAP-CAR，一種與標記的腫瘤特異性抗體共同管理的 CAR T 細胞治療平台，可能針對不同的腫瘤類型，包括血液惡性腫瘤和實體腫瘤；以及 CD38-Diagnostic，一種體外篩查工具，用於分析癌症患者是否可能適合接受抗 CD38 單克隆抗體治療。</p>
<h2>另見</h2>
<ul>
<li>我們更看好的五隻股票比 Coeptis Therapeutics 更好</li>
<li>便士股票適合你的投資組合嗎？</li>
<li>感恩節餐桌上有什麼？每道菜的股票選擇</li>
<li>FAANG 股票是什麼，它們是好的投資嗎？</li>
<li>為什麼家得寶的痛苦可能是長期投資者的收益</li>
<li>股息篩選器：如何在購買前評估股息股票</li>
<li>高通的牛市正在失去犯錯的空間</li>
</ul>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 Coeptis Therapeutics 嗎？</h2>
<p>在你考慮 Coeptis Therapeutics 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦現在購買，以便在更廣泛的市場注意到之前……而 Coeptis Therapeutics 並不在名單上。</p>
<p>雖然 Coeptis Therapeutics 目前在分析師中被評為賣出評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

COEP

<p>Coeptis Therapeutics（納斯達克代碼：COEP）股票上漲 12.2%，至 17.00 美元，交易量較平均水平增加 92%。儘管股價上漲，Weiss Ratings 仍重申了 “賣出” 評級。該公司市值為 9078 萬美元，開發用於癌症的細胞治療平台。機構投資者持有該股票的 13.88%。Yorkville Advisors 最近獲得了新的股份。分析師建議其他股票可能是更好的投資選擇</p>

<p>Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP - Get Free Report) shares rose 12.2% on Tuesday . The stock traded as high as $17.13 and last traded at $17.00. Approximately 77,154 shares changed hands during mid-day trading, an increase of 92% from the average daily volume of 40,114 shares. The stock had previously closed at $15.15.</p>
<div class="lb-trans"><p>Coeptis Therapeutics Holdings, Inc.（納斯達克代碼：COEP - 獲取免費報告）週二股價上漲了 12.2%。該股最高交易價為 17.13 美元，最後交易價為 17.00 美元。在午盤交易中，約有 77,154 股易手，較日均交易量 40,114 股增加了 92%。該股此前收盤價為 15.15 美元。</p>
</div><p>Get <strong>Coeptis Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Coeptis Therapeutics</strong> 的提醒：</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析師升級與降級</h2>
</div><p>Separately, Weiss Ratings reaffirmed a &#34;sell (e+)&#34; rating on shares of Coeptis Therapeutics in a research report on Wednesday, October 8th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Coeptis Therapeutics presently has a consensus rating of &#34;Sell&#34;.</p>
<div class="lb-trans"><p>另外，Weiss Ratings 在 10 月 8 日星期三的研究報告中重申了對 Coeptis Therapeutics 股票的 “賣出（e+）” 評級。一位投資分析師對該股給予了賣出評級，根據 MarketBeat.com 的數據，Coeptis Therapeutics 目前的共識評級為 “賣出”。</p>
</div><p><strong>Read Our Latest Stock Report on Coeptis Therapeutics</strong></p>
<div class="lb-trans"><p><strong>閲讀我們關於 Coeptis Therapeutics 的最新股票報告</strong></p>
</div><h2>Coeptis Therapeutics Trading Up 12.2%</h2>
<div class="lb-trans"><h2>Coeptis Therapeutics 股價上漲 12.2%</h2>
</div><p>The stock has a market cap of $90.78 million, a P/E ratio of -5.18 and a beta of -0.50. The firm's 50 day simple moving average is $15.16 and its two-hundred day simple moving average is $11.96. The company has a quick ratio of 0.83, a current ratio of 2.21 and a debt-to-equity ratio of 0.01.</p>
<div class="lb-trans"><p>該股市值為 9078 萬美元，市盈率為-5.18，貝塔值為-0.50。該公司的 50 日簡單移動平均線為 15.16 美元，200 日簡單移動平均線為 11.96 美元。公司的速動比率為 0.83，流動比率為 2.21，債務股本比率為 0.01。</p>
</div><h2>Institutional Investors Weigh In On Coeptis Therapeutics</h2>
<div class="lb-trans"><h2>機構投資者對 Coeptis Therapeutics 的看法</h2>
</div><p>A hedge fund recently bought a new stake in Coeptis Therapeutics stock. Yorkville Advisors Global LP bought a new stake in Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP - Free Report) in the third quarter, according to its most recent 13F filing with the Securities &amp; Exchange Commission. The fund bought 8,000 shares of the company's stock, valued at approximately $140,000. Coeptis Therapeutics accounts for about 0.0% of Yorkville Advisors Global LP's portfolio, making the stock its 24th largest holding. Yorkville Advisors Global LP owned 0.17% of Coeptis Therapeutics as of its most recent SEC filing. Institutional investors own 13.88% of the company's stock.</p>
<div class="lb-trans"><p>一家對沖基金最近在 Coeptis Therapeutics 股票中購買了新股份。Yorkville Advisors Global LP 在第三季度購買了 Coeptis Therapeutics Holdings, Inc.（納斯達克代碼：COEP - 免費報告）的新股份，根據其最近向證券交易委員會提交的 13F 文件，該基金購買了 8,000 股該公司的股票，價值約為 140,000 美元。Coeptis Therapeutics 佔 Yorkville Advisors Global LP 投資組合的約 0.0%，使該股成為其第 24 大持股。截至其最近的 SEC 文件，Yorkville Advisors Global LP 持有 Coeptis Therapeutics 的 0.17%。機構投資者持有該公司 13.88% 的股票。</p>
</div><h2>About Coeptis Therapeutics</h2>
<div class="lb-trans"><h2>關於 Coeptis Therapeutics</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Coeptis Therapeutics Holdings, Inc, a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy.</p>
<div class="lb-trans"><p>Coeptis Therapeutics Holdings, Inc.是一家生物製藥公司，開發針對癌症患者的細胞治療平台。其產品組合包括 CD38-GEAR-NK，一種用於治療與 CD38 相關的癌症的細胞治療，包括多發性骨髓瘤、慢性淋巴細胞白血病和急性髓性白血病；SNAP-CAR，一種與標記的腫瘤特異性抗體共同管理的 CAR T 細胞治療平台，可能針對不同的腫瘤類型，包括血液惡性腫瘤和實體腫瘤；以及 CD38-Diagnostic，一種體外篩查工具，用於分析癌症患者是否可能適合接受抗 CD38 單克隆抗體治療。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另見</h2>
</div><ul>
<li>Five stocks we like better than Coeptis Therapeutics</li>
<li>Are Penny Stocks a Good Fit for Your Portfolio?</li>
<li>What’s on the Thanksgiving Table? A Stock Pick for Every Course</li>
<li>What Are the FAANG Stocks and Are They Good Investments?</li>
<li>Why Home Depot’s Pain Could Be a Long-Term Investor’s Gain</li>
<li>Dividend Screener: How to Evaluate Dividend Stocks Before Buying</li>
<li>Qualcomm’s Bulls Are Running Out of Room to Be Wrong</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票比 Coeptis Therapeutics 更好</li>
<li>便士股票適合你的投資組合嗎？</li>
<li>感恩節餐桌上有什麼？每道菜的股票選擇</li>
<li>FAANG 股票是什麼，它們是好的投資嗎？</li>
<li>為什麼家得寶的痛苦可能是長期投資者的收益</li>
<li>股息篩選器：如何在購買前評估股息股票</li>
<li>高通的牛市正在失去犯錯的空間</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Coeptis Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Coeptis Therapeutics 嗎？</h2>
</div><p>Before you consider Coeptis Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮 Coeptis Therapeutics 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Coeptis Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦現在購買，以便在更廣泛的市場注意到之前……而 Coeptis Therapeutics 並不在名單上。</p>
</div><p>While Coeptis Therapeutics currently has a Sell rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Coeptis Therapeutics 目前在分析師中被評為賣出評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Coeptis Therapeutics (NASDAQ:COEP) 股價上漲 12.2% - 接下來會如何發展？